• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Improvement in anti-hemophilic preparations and its problems. 7. Present status and future aspect of anti-hemophilic preparations].

作者信息

Kamiya T

出版信息

Rinsho Ketsueki. 1988 May;29(5):666-70.

PMID:3145998
Abstract
摘要

相似文献

1
[Improvement in anti-hemophilic preparations and its problems. 7. Present status and future aspect of anti-hemophilic preparations].[抗血友病制剂的改进及其问题。7. 抗血友病制剂的现状与未来展望]
Rinsho Ketsueki. 1988 May;29(5):666-70.
2
[Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
Rinsho Ketsueki. 1988 May;29(5):628-34.
3
[Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].[抗血友病制剂的改进及其问题。3. 伴有抑制剂的血友病患者的治疗；低剂量或中等剂量方案诱导免疫耐受]
Rinsho Ketsueki. 1988 May;29(5):640-8.
4
[Virus in hemophilia: current status and future perspectives].[血友病中的病毒：现状与未来展望]
Sangre (Barc). 1996 Apr;41(2):141-5.
5
Blood safety and the choice of anti-hemophilic factor concentrate.
Pediatr Blood Cancer. 2007 Jan;48(1):117. doi: 10.1002/pbc.21086.
6
[Improvement in anti-hemophilic preparations and its problems. 4. Factor VIII preparation (RCG-5) with intermediate purity and potency].[抗血友病制剂的改进及其问题。4. 中等纯度和效价的凝血因子VIII制剂（RCG-5）]
Rinsho Ketsueki. 1988 May;29(5):649-54.
7
Correlation of antibodies to LAV/HTLV III in hemophiliacs with the use of virus-inactivated clotting factors.血友病患者中抗LAV/HTLV III抗体与使用病毒灭活凝血因子的相关性。
Thromb Haemost. 1986 Aug 20;56(1):50-2.
8
[Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
Sangre (Barc). 1979;24(5-C):937-41.
9
Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.接受中等纯度因子VIII浓缩物或因子IX复合物治疗的既往未治疗患者中抑制剂发生率为零。
Thromb Haemost. 1995 Mar;73(3):553-5.
10
Modern treatment of hemophilia: from the shadows towards the light.血友病的现代治疗：从阴影走向光明。
Thromb Haemost. 1993 Jul 1;70(1):17-23.